Pasithea Therapeutics (KTTA) Operating Expenses (2021 - 2024)
Historic Operating Expenses for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to $3.3 million.
- Pasithea Therapeutics' Operating Expenses fell 3669.28% to $3.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $14.2 million, marking a year-over-year decrease of 1082.27%. This contributed to the annual value of $14.2 million for FY2024, which is 1082.27% down from last year.
- According to the latest figures from Q4 2024, Pasithea Therapeutics' Operating Expenses is $3.3 million, which was down 3669.28% from $3.0 million recorded in Q3 2024.
- Pasithea Therapeutics' 5-year Operating Expenses high stood at $5.1 million for Q4 2023, and its period low was $549609.0 during Q1 2021.
- Its 4-year average for Operating Expenses is $2.9 million, with a median of $3.1 million in 2023.
- Its Operating Expenses has fluctuated over the past 5 years, first surged by 39701.48% in 2022, then crashed by 3669.28% in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Operating Expenses stood at $2.0 million in 2021, then skyrocketed by 106.89% to $4.0 million in 2022, then increased by 27.36% to $5.1 million in 2023, then plummeted by 36.69% to $3.3 million in 2024.
- Its Operating Expenses was $3.3 million in Q4 2024, compared to $3.0 million in Q3 2024 and $3.9 million in Q2 2024.